2nd Department of General Surgery, Jagiellonian University Medical College, Kopernika 21, Kraków, Poland.
Centre for Research, Training and Innovation and Surgery (CERTAIN Surgery), Kraków, Poland.
Med Oncol. 2017 Oct 30;34(12):188. doi: 10.1007/s12032-017-1047-6.
Most current guidelines do not recommend primary tumor resection in stage IV unresectable colorectal cancer. Rapid chemotherapy development over the last decade has substantially changed the decision making. However, results of recently published trials and meta-analyses suggest that primary tumor resection may in fact be beneficial, principally in terms of prolonged survival. Additional factors, such as use of minimally invasive approach or protocols of enhanced recovery after surgery, affect clinical outcomes as well, but are often neglected when discussing the state of the art in this area. There are still no randomized studies determining the legitimacy of upfront surgery in asymptomatic patients. Also, quality of life also plays an important role in choosing appropriate treatment. Having said that, there is no data that would prove whether primary tumor resection has an advantage on that issue. With all the uncertainty, currently decision making in unresectable stage IV colorectal cancer is primarily up to clinicians' knowledge, common sense and patients' preferences.
大多数现行指南不建议对不可切除的 IV 期结直肠癌进行原发肿瘤切除术。过去十年中,快速发展的化疗已极大地改变了决策。然而,最近发表的试验和荟萃分析结果表明,原发肿瘤切除术实际上可能是有益的,主要是在延长生存方面。其他因素,如微创方法的使用或手术后强化康复方案,也会影响临床结果,但在讨论该领域的最新进展时往往被忽视。目前仍没有随机研究确定在无症状患者中进行 upfront surgery 的合理性。此外,生活质量在选择合适的治疗方法中也起着重要作用。话虽如此,但目前尚无数据证明原发肿瘤切除术在这方面具有优势。鉴于所有的不确定性,目前不可切除的 IV 期结直肠癌的决策主要取决于临床医生的知识、常识和患者的偏好。